Last, we suggest that pharmacological HAS inhibition by 4-MU or 4-MUG and combination therapy with anti–PD-1 antibody could be a treatment option for patients with CRC liver metastasis with MASLD. This evidence concerns the gene PDCD1 and colorectal carcinoma.